Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Next Previous
X
Search
Trial Profile

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms RIVETING STUDY
  • Sponsors Pfizer

    • Most Recent Events

    • 17 Oct 2023 Results assessing final safety analyses from the tofacitinib UC ((NCT00787202; NCT01465763; NCT01458951; NCT01458574,NCT01470612, NCT03281304) presented at the 31st United European Gastroenterology Week
    • 09 May 2023 Results of Updated 30 Month Data from the Double-Blind, Randomized Riveting Study presented at the Digestive Disease Week 2023
    • 05 Jan 2023 Results of a post-hoc pooled analysis assessing herpes zoster incidence and risk factors from following clinical trials: NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612 and NCT03281304 published in the Inflammatory Bowel Diseases

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top